N/A N=45 A High Density EEG Comparison of Sleep Patterns in Insomnia
Primary Insomnia
Primary: EEG Power During Sleep — 1.40; 1.17 μV^2/Hz — p=0.2791
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=137 Sleep Specialty Consultation: Improving Management of Sleep Disorders
Sleep Disorders
Primary: Provider Adherence to Sleep Specialist Recommendations — 4; 0; 8; 4 participants
N/A N=100 Mechanisms of Sleep Disruption Hyperalgesia
Sleep Deprivation · Pain
Primary: Spinal Sensitization as Assessed by Area of Secondary Hyperalgesia (2HA) After Two Nights of Uninterrupted Sleep and Two Nights of 8 Forced Awakenings — 1276.25…
Phase 2 N=20 Effect of Background Noise on Sleep Quality
Sleep Onset Insomnia
Primary: Sleep Onset Latency (Mins) — 13; 19 minutes — p=0.011
N/A N=59 Pharmacotherapy and Mechanisms of Sleep Disturbance in Alcohol Dependence
Alcohol Dependence · Insomnia
Primary: Percentage of Total Sleep Time in Stage 2 Sleep Pre- and Post-study Medication (Stage 2 Percent) — 51.3; 53.8; 50.2; 59.6 percentage of total sleep time
N/A N=124 Cognitive Behavioral Treatments for Post-traumatic Stress Disorder (PTSD) Sleep Disturbance
Post-traumatic Stress Disorder
Primary: Weekly Number of Nightmares — 3.95; 3.88; 3.28; 3.47 weekly nightmares
N/A N=92 Sleep IntervEntion as Symptom Treatment for ADHD
ADHD · Sleep · Adolescents
Primary: Sleep Architecture Objective TST [Total Sleep Time] Pre-test to Post-test — 8.11; 7.94; 8.03; 8.07 hours — p=.17
N/A N=118 Light Treatment for Sleep/Wake Disturbances in Alzheimer's Disease
Sleep Initiation and Maintenance Disorders
Primary: Total Sleep Time — 393; 420; 398; 409 units on a scale (minutes)
Phase 4 N=27 Atripla to Stribild Switch Study to Evaluate Sleep Disturbances
HIV · AIDS · Sleep Disorders
Primary: Percentage of Patients With Viral Loads < 50 Following the Switch — 20 Participants
N/A N=40 Treatment of Sleep Disturbances in Young Children With Autism
Autism · Autism Spectrum Disorders
Primary: Modified Simond & Parraga Sleep Questionnaire (MSPSQ) - Composite Sleep Index — 6.53; 7.44; 4.80; 6.83 units on a scale
N/A N=92 Improving Sleep Using Mentored Behavioral and Environmental Restructuring
Insomnia
Primary: Sleep Efficiency (SE) — 76.1 percentage of time in bed
Phase 4 N=19 The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia
Sleep Disorders · Fibromyalgia · Sleep
Primary: Number of Awakenings After Sleep Onset (NAASO) — 39.5; 34.9 Awakenings — p=0.424
N/A N=489 Implementing and Sustaining a Sleep Treatment to Improve Community Mental Part 1: Implementation Health Outcomes
Sleep Disorder · Circadian Dysregulation
Primary: Patient-level Outcome: Patient-Reported Outcomes Measurement Information System - Sleep Disturbance — 63.86; 62.10; 62.81; 62.80 T-score — p=<0.001
N/A N=154 Behavioral Treatment of Menopausal Insomnia; Sleep and Daytime Outcomes
Menopause
Primary: Diary Based Sleepiness — 5.01; 5.13; 4.87; 4.72 score on a scale
N/A N=38 Examining the Association Between Pre-existing Sleep Disturbance and Postoperative Delirium
Delirium
Primary: Association Between Sleep and POD — 278.5; 313.5 Minutes
N/A N=22 Treating Co-Morbid Sleep Difficulties in Veterans With Posttraumatic Stress Disorder (PTSD): A Pilot Study
Posttraumatic Stress Disorder · Insomnia
Primary: Insomnia Severity — 21.58; 12.45 ISI Score
N/A N=20 Sleep Loss and Mechanisms of Impaired Glucose Metabolism
Primary Insomnia
Primary: Change in Glucose Tolerance (Kg) in Response to Insulin-modified Intravenous Glucose Tolerance Test — .33; -0.10 %/min, slope of natural log glucose
Phase 4 N=27 Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder
Post-Traumatic Stress Disorders
Primary: Short PTSD Rating Interview (SPRINT) — 16.13; 19.88 units on a scale
N/A N=28 Hyper-Arousal in Chronic Primary Insomnia
Chronic Insomnia
Primary: Sympathetic Baroreflex Sensitivity (BRS) Unit — -2.1; -4.3 bursts per 100 heart beats per mm Hg
N/A N=28 The Psychoneuroimmunology of Insomnia
Primary Insomnia
Primary: Positive Antibody Response — 7; 7 participants
N/A N=30 Sleep, Hypertension, and Nocturia: a Multicomponent Approach for Comorbid Illnesses
Nocturia · Hypertension · Sleep Disturbance
Primary: Change in Mean Sleep Time Systolic Blood Pressure Dip Pre- vs Post-intervention — -0.4; 7.3; 3.9 percentage of daytime mean SBP — p=0.65
N/A N=14 A Sleep Intervention in Type 1 Diabetes
Short Sleep Phenotype · Type1diabetes
Primary: Sleep Duration — 385; 388 minutes
Phase 3 N=44 Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive Disorder
Sleep Disturbances
Primary: Changes From Baseline to Week 8 on Sleep Quality as Assessed by Polysomnographic Recorded (PSG) Parameters — -24.9; -19.7; -26.4; 49.0 minutes (min)
N/A N=149 Sleep Quality and Mechanisms of Cardiovascular Risks in Adults With Hypertension
Hypertension · Insomnia
Primary: Change in Blood Pressure During the Nighttime Sleep Period — -2.48; -1.90 mmHg — p=0.002
Phase 3 N=30 Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone
Parkinson's Disease · Insomnia
Primary: TST — 5.7; 6.0 hours
N/A N=30 Chronic Insomnia and CSF Markers of Dementia
Insomnia Chronic
Primary: CSF Markers Related to Dementia — 4332.1; 4824.0; 393.2; 419.4 picograms per milliliter
N/A N=159 Implementing Sleep Interventions for Older Veterans
Insomnia
Primary: Sleep Onset Latency — 21.3; 31.3 Minutes — p=<.001
Phase 4 N=115 Partial Reinforcement II: Three Approaches to Maintenance Therapy for Chronic Insomnia
Insomnia · Insomnia Chronic
Primary: Treatment Response (Phase 1) — 94 Participants
Phase 4 N=67 Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes
Type 2 Diabetes Mellitus · Insomnia · Sleep Disorder
Primary: Subjective Total Sleep Time — 6.4; 7.0; 6.7; 6.7 hours — p=0.15
N/A N=188 Sleep Without Insomnia or The Use of Chronic Hypnotics
Sleep Initiation and Maintenance Disorders
Primary: Rates of Hypnotic Discontinuation — 64; 52 Participants — p=.039